JAPhA: A Data-Driven Quality-Score System
Valisure’s Co-Founder & President, David Light, is credited as a co-author in a peer-reviewed paper published in the Journal of the American Pharmacists Association titled: “A Data-Driven Quality-Score System for Rating Drug Products and Its Implications for the Health Care Industry.”
The paper proposes a groundbreaking quality-score system driven by independent chemical testing and regulatory data to help differentiate drug products based on their manufacturing quality—a critical gap in current pharmaceutical procurement practices.
Amid increasing concerns over the integrity of the U.S. drug supply, the publication underscores that buyers and payers of pharmaceuticals often lack visibility into the quality of the products they source. The proposed system offers a solution: generate quality scores based on both public regulatory data and independently derived laboratory data, including the kind of chemical batch validation pioneered by Valisure.
Key highlights of the paper include:
- A framework for integrating quality scores into health system procurement decisions
- Incentives for manufacturers to prioritize higher-quality drug production
- A pathway toward greater accountability and transparency across the supply chain
- Improved decision-making that balances cost with quality
“Incorporating independent, data-driven quality metrics into procurement decisions has the potential to transform the drug supply chain and better protect patients,” said David Light, Co-Founder & President of Valisure.
This research adds to Valisure’s growing body of work that supports national efforts to raise the standards of pharmaceutical safety, improve sourcing practices, and strengthen trust in the U.S. healthcare system.
